Ovid Therapeutics (OVID) Enterprise Value (2020 - 2025)
Ovid Therapeutics (OVID) has disclosed Enterprise Value for 6 consecutive years, with -$25.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 58.19% year-over-year to -$25.5 million, compared with a TTM value of -$25.5 million through Sep 2025, up 58.19%, and an annual FY2024 reading of -$53.1 million, up 48.54% over the prior year.
- Enterprise Value was -$25.5 million for Q3 2025 at Ovid Therapeutics, up from -$38.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$25.5 million in Q3 2025 and bottomed at -$233.1 million in Q1 2021.
- Average Enterprise Value over 5 years is -$116.1 million, with a median of -$103.1 million recorded in 2023.
- The sharpest move saw Enterprise Value crashed 414.29% in 2021, then soared 58.19% in 2025.
- Year by year, Enterprise Value stood at -$187.8 million in 2021, then soared by 32.83% to -$126.1 million in 2022, then increased by 18.25% to -$103.1 million in 2023, then soared by 48.54% to -$53.1 million in 2024, then skyrocketed by 52.0% to -$25.5 million in 2025.
- Business Quant data shows Enterprise Value for OVID at -$25.5 million in Q3 2025, -$38.3 million in Q2 2025, and -$40.8 million in Q1 2025.